Table 6

Phase III first-line efficacy results

Treatment armn% Response rate (95% CI)aMedian progression-free survival (days) (95% CI)Median survival (days) (95% CI)P (survival)
Gemcitabine + cisplatin +
 250 mg gefitinib36550.1 (44.7–55.6)178 (153–190)299 (255–325)0.4832
 500 mg gefitinib36549.7 (44.2–55.2)169 (144–187)268 (242–316)0.3041
 Placebo36344.8 (39.3–50.4)182 (166–188)302 (272–342)
Paclitaxel + carboplatin +
 250 mg gefitinib34735.0 (29.6–40.6)162 (133–175)300 (264–334)0.6429
 500 mg gefitinib34532.1 (27.0–37.7)142 (127–160)302 (268–352)0.6710
 Placebo34533.6 (28.1–39.3)154 (132–176)337 (307–368)
  • a CI, confidence interval.